Look up one drug

Matched class: 28:20 C.N.S. Stimulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MIXED SALT AMPHETAMINE Some products covered without a code (check the product listing): LISDEXAMFETAMINE DIMESYLATE, METHYLPHENIDATE HCL 28:20 C.N.S. Stimulants

LISDEXAMFETAMINE DIMESYLATE

· 60 products · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg · Cap, Chew Tab

METHYLPHENIDATE HCL

· 47 products · General benefit (43), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 25mg, 35mg, 45mg, 55mg, 70mg, 85mg, 100mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 80mg, 18mg, 27mg, 36mg, 54mg · CR Cap, ER Cap, ER Tab, SR Tab, Tab

MIXED SALT AMPHETAMINE

· 24 products · General benefit · strengths: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg · ER Cap

MODAFINIL

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:20

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: MIXED SALT AMPHETAMINE GUANFACINE · Limited Use, codes 540 Indications Pediatrics (6 to 17 years of age) INTUNIV XR (guanfacine hydrochloride extended-release tablets) is indicated as: • monotherapy for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10 Product monograph Need for Comprehensive Treatment Program INTUNIV XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10 Product monograph MIXED SALT AMPHETAMINE · General benefit Indications ADDERALL XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: • Children (6 – 12 years of age) • Adolescents (13 – 17 years of age) • Adults (18 years of age or older) Need for Comprehensive Treatment Program ADDERALL XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081719.PDF; date 2025-09-12; DIN 02248808; fetched 2026-09-10 Product monograph ATOMOXETINE HCL · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) Need for Comprehensive Treatment Program TEVA-ATOMOXETINE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00052053.PDF; date July 2, 2019; DIN 02314541; fetched 2026-09-10 Product monograph LISDEXAMFETAMINE DIMESYLATE · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) Need for Comprehensive Treatment Program VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081828.PDF; date 2025-09-15; DIN 02322951; fetched 2026-09-10 Product monograph METHYLPHENIDATE HCL · General benefit (43), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) INDICATION AND CLINICAL USE pms-METHYLPHENIDATE is indicated for the treatment of:  Attention Deficit Hyperactivity Disorder (ADHD) Need for Comprehensive Treatment Program pms-METHYLPHENIDATE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00068339.PDF; date October 17, 2022; DIN 00584991; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

1 INDICATIONS DEXEDRINE/DEXEDRINE SPANSULE (dextroamphetamine sulfate) is indicated: • in the adjunctive treatment of narcolepsy • for the treatment of attention deficit hyperactivity disorder (ADHD) Attention Deficit Hyperactivity Disorder (ADHD): A diagnosis of ADHD (DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and that were present before age 7 years. The symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes, lack of sustained attention, poor listener, failure to follow through on tasks, poor organization, avoids tasks requiring sustained mental effort, loses things, easily distracted, forgetful. For the Hyperactive-Impulsive Type, at least 6… https://pdf.hres.ca/dpd_pm/00083629.PDF PM date: FEB 25, 2026 Source product: DEXEDRINE; DIN 01924516; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.